Illustrative image.

Lynparza

Name: Lynparza
Brand: Astra Zeneca
Availability: InStock

Olaparib

Prescription required

$8895.00

100mg · 3 × 56 tablets · 3 months supply

BrandBranded medicine

$2965.00 per month

Strength

How long a supply?

1 month$2965.00 a monthOne-off$2965.00

3 months$2965.00 a monthOne-off$8895.00

6 months$2965.00 a monthOne-off$17790.00

Supplied from Turkey

Test mode: no payment is taken. View cart

Annual cost

$38545a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

100mg

150mg

About Lynparza

Overview

Lynparza (olaparib) is a prescription cancer medicine supplied as tablets. It is used in adults with certain ovarian, fallopian tube, primary peritoneal, breast, pancreatic or prostate cancers, depending on genetic test results and previous treatment. Depending on the cancer and treatment setting, it may be used alone or with other medicines, including as maintenance treatment after chemotherapy. It blocks PARP enzymes involved in repairing DNA, which can lead to DNA damage and cancer cell death.

What it treats

Lynparza is used in adults for: • Maintenance treatment of advanced or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer with a harmful or suspected harmful BRCA mutation, after a complete or partial response to platinum-based chemotherapy. For advanced cancer, this follows first-line chemotherapy. • Maintenance treatment with bevacizumab for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer that is homologous recombination deficiency (HRD)-positive, after a complete or partial response to first-line platinum-based chemotherapy. HRD-positive status means a harmful or suspected harmful BRCA mutation, genomic instability, or both. • Additional treatment of high-risk, early HER2-negative breast cancer with an inherited harmful or suspected harmful BRCA mutation, after chemotherapy given before or after surgery. • Treatment of metastatic HER2-negative breast cancer with an inherited harmful or suspected harmful BRCA mutation, following chemotherapy. For hormone receptor-positive cancer, prior endocrine therapy is required unless it is unsuitable. • Maintenance treatment of metastatic pancreatic adenocarcinoma with an inherited harmful or suspected harmful BRCA mutation, when the cancer has not progressed during at least 16 weeks of first-line platinum-based chemotherapy. • Treatment of metastatic castration-resistant prostate cancer with a harmful or suspected harmful inherited or acquired homologous recombination repair (HRR) gene mutation, after progression on enzalutamide or abiraterone. • Treatment with abiraterone and prednisone or prednisolone for metastatic castration-resistant prostate cancer with a harmful or suspected harmful BRCA mutation. An FDA-approved companion diagnostic test is used to select patients for treatment.

Safety information

Side effects

Common side effects of Lynparza used alone include nausea, tiredness or weakness, anemia (low red blood cells), vomiting, diarrhea, reduced appetite, headache, changes in taste, cough, shortness of breath, dizziness, indigestion, and low white blood cell or platelet counts. When used with bevacizumab, common side effects include nausea, tiredness or weakness, anemia, low white blood cell counts, vomiting, diarrhea, urinary tract infection and headache. When used with abiraterone and prednisone or prednisolone, common side effects include anemia, tiredness, nausea, diarrhea, reduced appetite, low lymphocyte counts (a type of white blood cell), dizziness and abdominal pain. Serious side effects that warrant prompt contact with a doctor include bone marrow disorders or blood cancer (myelodysplastic syndrome or acute myeloid leukemia), lung inflammation (pneumonitis), blood clots in the veins or lungs, and liver injury. Some of these reactions have been fatal. Blood tests are needed before treatment and monthly during treatment to monitor for blood-related toxicity. Lynparza can harm an unborn baby. Effective contraception is needed; contact your doctor if you become pregnant during treatment.

Before taking this medicine

The FDA label lists no contraindications for Lynparza. However, serious risks require caution and monitoring: • Myelodysplastic syndrome and acute myeloid leukemia, serious blood and bone marrow disorders, have occurred and can be fatal. Blood counts should be checked before treatment and monthly thereafter. Treatment must be stopped if either condition is confirmed. • Pneumonitis (lung inflammation) has occurred, including fatal cases. Treatment should be interrupted if suspected and stopped if confirmed. • Blood clots in veins, including severe or fatal clots in the lungs, have occurred. Monitoring for signs and symptoms is needed. • Liver toxicity, including drug-induced liver injury, has occurred. Treatment should be interrupted if drug-induced liver injury is suspected and stopped if confirmed. • Lynparza can harm an unborn baby. Effective contraception is needed. • Women should not breastfeed during treatment.

Interactions

Tell your doctor about medicines you take that are strong or moderate CYP3A inhibitors or inducers, as these should be avoided with Lynparza. If a CYP3A inhibitor cannot be avoided, your prescriber will need to reduce your Lynparza dose.

Using Lynparza

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label LYNPARZA (OLAPARIB) TABLET, FILM COATED [ASTRAZENECA PHARMACEUTICALS LP] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.